31 results about "Selective estrogen receptor modulators" patented technology

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, and uses thereof.

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, sublingual administration, topical administration, transdermal administration, or combinations thereof and uses thereof.

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, and uses thereof.

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, and uses thereof.

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, and uses thereof.

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, and uses thereof.

The present invention provides compositions and methods of their use in treating dystroglycanopathy, muscular dystrophy and other disorders. In particular, a method of treating a disorder associated with a mutation or loss of function in a fukutin related protein (FKRP) gene and / or a disorder associated with a defect in glycosylation of α-DG in a subject is provided, comprising administering to the subject an effective amount of a ribitol and a selective estrogen receptor modulator (SERM).

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, and uses thereof.

The invention relates to the field of antibacterial gels, in particular to an ovary maintenance antibacterial gel as well as a preparation method and application thereof. The invention relates to an ovary maintenance antibacterial gel, which comprises a component A, a component B and a component C, the component A is prepared from 64 to 84 parts of deionized water, 0.05 to 0.15 part of preservative synergist, 0.6 to 0.9 part of carbomer U-30, 0.06 to 0.12 part of ultra-high molecular weight hyaluronic acid, 3 to 7 parts of hydrogel, 3 to 6 parts of glycerol and 3 to 6 parts of propylene glycol; the component B is prepared from 3 to 7 parts of selective estrogen receptor regulator and 0.5 to 2.5 parts of flos lonicerae extract; the component C is prepared from the following components in parts by weight: 0.1 to 0.3 part of silver ion solution, 0.3 to 0.6 part of preservative, 0.05 to 0.15 part of tween-20 and 0.05 to 0.25 part of triethanolamine. The gel obtained in the invention is applied to ovaries, can play a role in bacteriostasis, and can also effectively improve premature ovarian failure.

Described herein are compositions comprising a lanthanide (III) modified fatty acid and methods of treating cancer with the composition. In particular, the application includes a lanthanide (III) modified fatty acid is a 9-R′, 10-R″ tri octadecanoate compound. This lanthanide (III) modified fatty acid can be combined with additional therapeutic agents, such as chemotherapeutic agents, radiopharmaceuticals, hormone therapies, CDK inhibitors, epigenetic modulators, selective estrogen receptor modulators, selective estrogen receptor degraders, aromatase inhibitors, phosphatidyl inositol-3-posphate kinase inhibitors, ATP-adenosine axis-targeting agents, signal transduction inhibitors, RAS signaling inhibitors, PI3K inhibitors, arginase inhibitors, HIF inhibitors, AXL inhibitors, PAK4 inhibitors, immunotherapeutic agents, immune checkpoint inhibitors, and agonists of stimulatory or co-stimulatory immune checkpoints.

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, sublingual administration, topical administration, transdermal administration, or combinations thereof and uses thereof.

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, and uses thereof.

A selective estrogen receptor modulator and / or an aromatase inhibitor (A) for use in the treatment or prevention of gynecomastia, wherein said selective estrogen receptor modulator and / or aromatase in

The application relates to the field of bacteriostatic gels, in particular to an ovary maintenance bacteriostatic gel as well as a preparation method and application thereof. The ovary maintenance bacteriostatic gel comprises A component, B component and C component; the A component comprises the following components in parts by weight: deionized water 64-84 parts, preservative synergist 0.05-0.15 parts, Carbopol U-30 0.6-0.9 parts, super high molecular weight hyaluronic acid 0.06-0.12 parts, hydrogel 3-7 parts, glycerol 3-6 parts and propylene glycol 3-6 parts; the B component comprises the following components in parts by weight: selective estrogen receptor modulator 3-7 parts and radix viticis trifolia extract 0.5-2.5 parts; and the C component comprises the following components in parts by weight: silver ion solution 0.1-0.3 parts, preservative 0.3-0.6 parts, Tween-20 0.05-0.15 parts and triethanolamine 0.05-0.25 parts. The gel obtained by the application can not only play a bacteriostatic role when applied to ovaries, but also can effectively improve premature ovarian failure.

Useful processes of preparation and intermediates useful for the preparation of Compound 1, a selective estrogen receptor alpha (ERα) modulator / degrader (SERM / SERD), having utility for the treatment of ER+ cancers including breast cancer are described.

The present technology is directed to a method of treating a cancer, or multiple cancers, comprising administering to said individual one or more compounds selected from a VAV3-inhibitor such as IODVA1, followed by administration of a selective estrogen receptor modulator (SERM) and / or selective estrogen receptor degrader (SERD), to an individual in need thereof. In embodiments, the administration may be concurrently with or following IODVA1 administration.

Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.

Useful processes of preparation and intermediates useful for the preparation of Compound 1, a selective estrogen receptor alpha (ERα) modulator / degrader (SERM / SERD), having utility for the treatment of ER+ cancers including breast cancer are described.

Acute exposure to estrogenic chemicals is shown herein to induce DNA damage mediated by formation of ERα-dependent R-loops. Disclosed herein are methods for evaluating the safety and activity of a xenoestrogen. Also disclosed are methods for identifying subject particularly susceptible to the genotoxic effects of endogenous estrogens or environmental xenoestrogens. This method can be used to select suitable hormone therapies, such as a selective estrogen receptor modulator (SERM), aromatase inhibitor, or selective estrogen receptor degrader (SERD).

A selective estrogen receptor modulator and / or an aromatase inhibitor (A) for use in the treatment or prevention of gynecomastia, wherein said selective estrogen receptor modulator and / or aromatase in

This invention relates to combination therapy of a subject suffering from acromegaly. The method of treatment comprises administration to the subject of a therapeutically effective amount of oral somatostatin receptor ligand (SRL) e.g. octreotide in combination with a therapeutically effective amount of a dopamine agonist and / or a growth hormone receptor antagonist and / or a selective estrogen receptor modulator (SERM) and / or a 2nd somatostatin receptor ligand (SRL).

This invention relates to the treatment of breast cancer in a subject, and the subject can be either a male or female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), lerociclib, abemaciclib (Vorzenio), trilaciclib, lerociclib), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3Kα)), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; treating a subject suffering from ER mutant expressing breast cancer and / or treating breast cancer in a subject, by first determining the 18F-16β-fluoro-5α-dihydrotestosterone (18F-DHT) tumor uptake and identifying said subject as having AR-positive breast cancer based on 18F-DHT tumor uptake, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound and a cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor.

Disclosed is a method for treating of cancer, specifically pancreatic cancer by administering a selective estrogen receptor modulator (SERM), e.g., levormeloxifene, alone or in combination with one or more additional cancer therapies.

In various embodiments compositions for the treatment of testosterone deficiency (TD, or “low-T”) and / or secondary hypogonadotropic hypogonadism comprise at least one selective estrogen receptor modulator (SERM) and a carrier, wherein the composition is entirely devoid of any estrogenically active substances capable of lowering testosterone levels. In preferred embodiments, compositions comprise only the (E)-stereoisomer of clomiphene and are entirely devoid of the estrogenically active (Z)-stereoisomer of clomiphene. In various examples, compositions are enclosed in a rapidly disintegrating capsule configured for immediate release. In preferred embodiments, the carrier comprises microcrystalline cellulose that functions as both bulk filler and disintegrant.

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, and uses thereof.

A pharmaceutical composition capable of forming free burst release effect in-situ forming implant useful for injection inside bone injuries without surgery is provided. This pharmaceutical composition includes; biodegradable polymer, selective estrogen receptor modulator, organic solvent and liquid lipid, solidifies upon contacting with the surrounding medium and form solid implant with compact framework by in-situ phase separation method to deliver the selective estrogen receptor modulator. This compact framework restores the porous structure of the implant by time which is essential in promoting bone healing.

Provided herein are methods of treating a subject having benign prostatic hyperplasia that include, for example, identifying a subject having a white blood cell that has an elevated level of methylation of SRD5A2 as compared to a reference level; and administering to the identified subject a first therapy such as a combination therapy comprising a therapeutically effective amount of a 5-alpha reductase inhibitor and a selective estrogen receptor modulator.

Useful preparation processes and intermediates for the preparation of Compound 1, which are selective estrogen receptor alpha (ER alpha) modulators / degraders (SERM / SERD), which have utility in the treatment of ER + cancers, including breast cancer, are described.

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, sublingual administration, topical administration, transdermal administration, or combinations thereof and uses thereof.